David W. Hutton

David W. Hutton

Auto-generated profile, based on publicly available information

David W. Hutton

Department of Health Management and Policy University of Michigan School of Public Health Ann Arbor Michigan USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2014 in Health Affairs
Verified
Journal Article
Closed access
DHDavid Hutton
David Hutton
PNPaula Anne Newman-Casey
Paula Anne Newman-Casey
MTMrinalini Tavag
Mrinalini Tavag
DZDavid N Zacks
David N Zacks
JSJoshua Stein
Joshua Stein
The biologic drugs bevacizumab and ranibizumab have revolutionized treatment of diabetic macular edema and neovascular age-related macular degeneration, leading causes of blindness. Ophthalmologic ...

1 January 2020 in International Journal of Drug Policy
Verified
Journal Article
Closed access
TTTarlise Townsend
Tarlise Townsend
FBFreida Blostein
Freida Blostein
TDTran Doan
Tran Doan
SMSamantha Madson-Olson
Samantha Madson-Olson
PGPaige Galecki
Paige Galecki
DHDavid W. Hutton
David W. Hutton

14 December 2020 in Journal of Hepatology
Verified
Journal Article
Open access
AAAnton Avanceña
Anton Avanceña
NMNicholas Miller
Nicholas Miller
SUSarah E. Uttal
Sarah E. Uttal
DHDavid W. Hutton
David W. Hutton
JMJessica L. Mellinger
Jessica L. Mellinger
Alcohol use treatment such as medication-assisted therapies (MATs) and counseling are available and effective in promoting alcohol abstinence. We sought to explore the cost-effectiveness of different alcohol use treatments among patients with compensated alcohol-related cirrhosis (AC). We simulated a cohort of patients with compensated AC receiving care from a hepatology clinic over their lifetimes. We estimated costs (in 2017 US$) and benefits in terms of quality-adjusted life years (QALYs) gained from healthcare and societal perspectives. Transition probabilities, costs, and health utility weights were taken from the literature. Treatment effects of FDA-approved MATs (acamprosate and naltrexone) and non-FDA approved MATs (baclofen, gabapentin, and topiramate) and counseling were based on a study of employer-insured patients with AC. We calculated incremental cost-effectiveness ratios (ICERs) and performed one-way and probabilistic sensitivity analyses to understand the impact of parameter uncertainty. Compared to a do-nothing scenario, MATs and counseling were found to be cost-saving from a healthcare perspective, which means that they provide more benefits with less costs than no intervention. Compared to other interventions, acamprosate and naltrexone cost the least and provide the most QALYs. If the effectiveness of MATs and counseling decreased, these interventions would still be cost-effective based on the commonly used $100,000 per QALY gained threshold. Several sensitivity and scenario analyses showed that our main findings are robust. Among patients with compensated AC, MATs and counseling are extremely cost-effective, and in some cases cost-saving, interventions to prevent decompensation and improve health. Health policies (e.g. payer reimbursement) should emphasize and appropriately compensate for these interventions. Alcohol use treatments, including physician counseling and medication-assisted therapies (MATs), improve the outcomes of patients with compensated alcohol-related cirrhosis, though use and access have remained suboptimal. In this study, we found that counseling and MATs are extremely cost-effective, and in some cases cost-saving, interventions to help patients with alcohol-related cirrhosis abstain from alcohol and improve their health. Wider use of these interventions should be encouraged.

12 February 2020 in Annals of Surgery
Verified
Journal Article
Closed access
KRKavitha Ranganathan
Kavitha Ranganathan
PSPuneet Mhsa Singh
Puneet Mhsa Singh
KRKrishnan Mbbs Raghavendran
Krishnan Mbbs Raghavendran
EWEdwin G. Wilkins
Edwin G. Wilkins
JHJennifer B. Hamill
Jennifer B. Hamill
AMAdeyiza O. Momoh
Adeyiza O. Momoh
Objective: In this study, we quantified the global macroeconomic burden of breast cancer to underscore the critical importance of improving access to oncologic surgical care internationally. Summary Background Data: Breast cancer mortality in many low and middle-income countries (LMICs) is dramatically higher than in high-income countries. Prior to identifying solutions, however, it is important to first define the burden of disease. Methods: Data from the Institute of Health Metrics and Evaluation (2005–2015) were used to assess epidemiologic trends for 194, middle, and low-income countries. Economic burden defined by Welfare Loss (WL) was calculated by measuring disability-adjusted-life-years lost to breast cancer alongside the dollar equivalent of a value of statistical life year and as a function of each country's gross domestic product (GDP). Results: Annual mortality rates among breast cancer patients were significantly greater in LMICs in South Asia (3.06 per 100 women) and Sub-Saharan Africa (2.76 per 100 women), compared with high-income countries like the United States (1.69 per 100 women). From 2005–2015, mortality in South Asia increased by 8.20% and decreased by 6.45% in Sub-Saharan Africa; mortality rates in 2015 were observed as 27.9 per 100,000 in South Asia and 18.61 per 100,000 in Sub-Saharan Africa. Countries in South Asia demonstrated the greatest rise in WL due to breast cancer, from 0.05% to 0.08% of GDP. Conclusions: The burden of disease and economic impact of breast cancer is intensifying in LMICs. Global efforts to improve access to surgical care for women with breast cancer could reduce mortality and mitigate the social and financial impact of this disease in LMICs.

4 September 2022 in European Heart Journal - Quality of Care and Clinical Outcomes
Verified
Journal Article
Open access
PDF file
RSRoland E Schmieder
Roland E Schmieder
FMFelix Mahfoud
Felix Mahfoud
Giuseppe ManciaGiuseppe Mancia
Giuseppe Mancia
KNKrzysztof Narkiewicz
Krzysztof Narkiewicz
LRLuis M. Ruilope
Luis M. Ruilope
JPJan B. Pietzsch
Jan B. Pietzsch
Renal denervation has been shown to lower blood pressure in sham-controlled trials and represents a device-based treatment option for hypertension. We sought to project clinical event reductions after radiofrequency renal denervation using a novel modelling approach. The Global SYMPLICITY Registry is a global, prospective all-comer registry to evaluate safety and efficacy after renal denervation. For this analysis, change in office systolic blood pressure from baseline was calculated from reported follow-up in the Global SYMPLICITY Registry. Relative risks for death and other cardiovascular events as well as numbers needed to treat for event avoidance were obtained for the respective blood pressure reductions based on previously reported meta-regression analyses for the full cohort and high-risk subgroups including type 2 diabetes, chronic kidney disease, resistant hypertension, and high basal cardiovascular risk. Average baseline office systolic blood pressure and reduction estimates for the full cohort (N = 2651) were 166±25 and −14.8 ± 0.4 mmHg, respectively. Mean reductions in blood pressure ranged from −11.0–−21.8 mmHg for the studied high-risk subgroups. Projected relative risks ranged from 0.57 for stroke in the resistant hypertension cohort to 0.92 for death in the diabetes cohort. Significant absolute reductions in major adverse cardiovascular events over 3 years compared with the projected control (8.6 ± 0.7% observed vs. 11.7 ± 0.9% for projected control; P < 0.01) were primarily due to reduced stroke incidence. The robustness of findings was confirmed in sensitivity and scenario analyses. Model-based projections suggest radiofrequency renal denervation for patients with uncontrolled hypertension adds considerable clinical benefit across a spectrum of different cohort characteristics.

1 December 2016 in Vaccine
Verified
Journal Article
Closed access
KMKristin A. Maurer
Kristin A. Maurer
HCHuey-Fen Chen
Huey-Fen Chen
AWAbram Wagner
Abram Wagner
SHSonia T. Hegde
Sonia T. Hegde
TPTejasi Patel
Tejasi Patel
DHDavid W. Hutton
David W. Hutton